News View

Definitive treatment of cutaneous leishmaniasis using nanotechnology

News Date : 2016-11-23 News Visited Count : 1208
Rate : 3
After years of investigation, researchers at Exirnanosina knowledge-based company have managed to produce nano-liposomal amphotericin B topical gel for definitive treatment of cutaneous leishmaniasis. This drug is a nano-liposomal topical gel which penetrates the skin to its deeper layers and cures the cutaneous leishmaniasis within 3 weeks.
Cutaneous leishmaniasis is a skin infection and the most common form of leishmaniasis which is transmitted through the bite of females of a specific species of sandfly; after biting, the person is infected with the parasite and an inflammatory red sore is appeared at location of the bite which lasts for 2 to 8 month.
Currently, 12 billion worldwide and 30 thousand people in Iran are suffering from cutaneous leishmaniasis. This number is increasing each year due to the resistance of the single-celled parasite causing this disease to the drugs, hence remaining of the parasite in human body. In addition, treatment of cutaneous leishmaniasis is very expensive, painful and associated with serious side effects. After years of investigation, researchers at Exirnanosina knowledge-based company have managed to produce nano-liposomal amphotericin B topical gel for definitive treatment of cutaneous leishmaniasis. This drug is a nano-liposomal topical gel which penetrates the skin to its deeper layers and cures the cutaneous leishmaniasis within 3 weeks.
Amphotericin B is an antifungal and antiparasitic drug often used for effective treatment of cutaneous leishmaniasis and local fungal infections. However, due to the renal toxicity of this, researchers have used the liposomal formulation to reduce the detrimental effects of this drug and improve the penetration of the drug to reach the fungus surface.
Liposome is the most common antibacterial drug delivery system. One of its distinguished properties include its lipid bilayer structure which mimics the cell membrane and readily fuse with infectious bacteria. Upon direct fusion with bacterial membrane, the drug is released inside the cell membrane or the bacteria. Therefore, using nano-liposom for drug delivery not only reduces the treatment side effects but also improves drug penetration and facilitate its transfer to fungus surface.
Currently, this product is mass produced at a lower cost than drugs conventionally used for cutaneous leishmaniasis. Also, it is easier to use and painless. Patients must use the gel twice a day for 3-4 weeks.
Nano-liposomal amphotericin B topical gel have been produced and patented in Exirnanosina Co. and it has received the NanoScale certificate from the product evaluation unit of Iran nanotechnology initiative council.

Opinion

Opinion

Reply to Return

Name
Email
Comment
Captcha (Case sensitive)